Cargando…

Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors

The immunotherapeutic catumaxomab targets EpCAM positive cancers and is approved for the treatment of peritoneal carcinomatosis. To assess the safety of intravenous applications a phase 1 clinical trial was initiated. Treatment of EpCAM positive tumor patients with catumaxomab caused dose dependent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borlak, Jürgen, Länger, Florian, Spanel, Reinhard, Schöndorfer, Georg, Dittrich, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053709/ https://www.ncbi.nlm.nih.gov/pubmed/27058902 http://dx.doi.org/10.18632/oncotarget.8574

Ejemplares similares

Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab
por: Seeber, Andreas, et al.
Publicado: (2015)

Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro
por: Seeber, Andreas, et al.
Publicado: (2015)

Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer
por: Knödler, Maren, et al.
Publicado: (2018)

The detection of EpCAM(+) and EpCAM(–) circulating tumor cells
por: Wit, Sanne de, et al.
Publicado: (2015)

Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas
por: Fong, Dominic, et al.
Publicado: (2014)

Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma
por: Armeanu-Ebinger, Sorin, et al.
Publicado: (2013)

EpCAM expression in squamous cell carcinoma of the uterine cervix detected by monoclonal antibody to the membrane-proximal part of EpCAM
por: Chantima, Warangkana, et al.
Publicado: (2017)

Expression of EpCAM in uveal melanoma
por: Odashiro, Danilo N, et al.
Publicado: (2006)

Biology and clinical relevance of EpCAM
por: Keller, Laura, et al.
Publicado: (2019)

EpCAM as Modulator of Tissue Plasticity
por: Fagotto, François
Publicado: (2020)

EpCAM (CD326) finding its role in cancer
por: Baeuerle, P A, et al.
Publicado: (2007)

EpCAM (CD326) finding its role in cancer
por: Baeuerle, P A, et al.
Publicado: (2007)

EpCAM(high) and EpCAM(low) circulating tumor cells in metastatic prostate and breast cancer patients
por: de Wit, Sanne, et al.
Publicado: (2018)

A genome-wide expression analysis identifies a network of EpCAM-induced cell cycle regulators
por: Maaser, K, et al.
Publicado: (2008)

EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex
por: Subramanian, Nithya, et al.
Publicado: (2015)

An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer
por: Liao, Mei-Ying, et al.
Publicado: (2015)

Current View on EpCAM Structural Biology
por: Gaber, Aljaž, et al.
Publicado: (2020)

Evolution of Thyroglobulin Loop Kinetics in EpCAM
por: Chen, Serena H., et al.
Publicado: (2021)

Characterization of human anti-EpCAM antibodies for developing an antibody–drug conjugate
por: Satofuka, Hiroyuki, et al.
Publicado: (2023)

Correction to: EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex
por: Subramanian, Nithya, et al.
Publicado: (2020)

EpCAM Knockdown Alters MicroRNA Expression in Retinoblastoma- Functional Implication of EpCAM Regulated MiRNA in Tumor Progression
por: Beta, Madhu, et al.
Publicado: (2014)

Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma
por: Salnikov, Alexei V, et al.
Publicado: (2009)

EpCAM proteolysis: new fragments with distinct functions?
por: Schnell, Ulrike, et al.
Publicado: (2013)

EpCAM and the biology of hepatic stem/progenitor cells
por: Dollé, Laurent, et al.
Publicado: (2014)

Functions of EpCAM in physiological processes and diseases (Review)
por: Huang, Li, et al.
Publicado: (2018)

Revisiting the Roles of Pro-Metastatic EpCAM in Cancer
por: Mohtar, M. Aiman, et al.
Publicado: (2020)

Development of a Novel Anti-EpCAM Monoclonal Antibody for Various Applications
por: Li, Guanjie, et al.
Publicado: (2022)

Correction: EpCAM Knockdown Alters MicroRNA Expression in Retinoblastoma- Functional Implication of EpCAM Regulated MiRNA in Tumor Progression
Publicado: (2015)

Effects of EpCAM overexpression on human breast cancer cell lines
por: Gostner, Johanna M, et al.
Publicado: (2011)

EpCAM (CD326) is differentially expressed in craniopharyngioma subtypes and Rathke’s cleft cysts
por: Thimsen, Vivian, et al.
Publicado: (2016)

Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies
por: Münz, Markus, et al.
Publicado: (2010)

Epithelial Mesenchymal Transition and Pancreatic Tumor Initiating CD44+/EpCAM+ Cells Are Inhibited by γ-Secretase Inhibitor IX
por: Palagani, Vindhya, et al.
Publicado: (2012)

Expression of EpCam and Villin in Barrett’s Esophagus and in Gastric Cardia
por: Anders, Mario, et al.
Publicado: (2008)

Selection and targeting of EpCAM protein by ssDNA aptamer
por: Alshaer, Walhan, et al.
Publicado: (2017)

EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs
por: Macdonald, Joanna, et al.
Publicado: (2018)

Clinicopathology of EpCAM and EGFR in Human Epithelial Ovarian Carcinoma
por: Zheng, Jingying, et al.
Publicado: (2017)

EpCAM(low) Circulating Tumor Cells: Gold in the Waste
por: Nicolazzo, Chiara, et al.
Publicado: (2019)

EpCAM tumor specificity and proteoform patterns in urothelial cancer
por: Dressler, Franz F., et al.
Publicado: (2023)

Immune Responses to Plant-Derived Recombinant Colorectal Cancer Glycoprotein EpCAM-FcK Fusion Protein in Mice
por: Lim, Chae-Yeon, et al.
Publicado: (2022)

Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model
por: Xu, Tianqi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_83drouktro9fu2uqilgng38int